Cenpl, short for Centromere protein L, is an important member of the centromere protein (CENP) family. It is involved in the mitotic process of eukaryotic cells, playing a crucial role in cell division. Although the specific associated pathways are not comprehensively detailed in the provided references, its significance in cell-cycle-related processes is emphasized [1,4].

Cenpl has been found to be upregulated in most cancers, including lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD), breast cancer, and hepatocellular carcinoma (HCC) [1-7, 9]. In LUAD, its upregulation and mutation are associated with a poorer prognosis, and it regulates cell proliferation, cell cycle, and is negatively correlated with the inflammation level and CD8+ T-cell infiltration [1]. In breast cancer, high Cenpl expression is related to cell cycle-associated processes, immune cell infiltration, and knockdown of Cenpl reduces cell proliferation and migration [3]. In HCC, Cenpl promotes cell proliferation, cell cycle progression, apoptosis, and glycolysis via the MEK1/2-ERK1/2 pathway, and serves as an independent prognostic factor [4]. In PAAD, overexpression of Cenpl mRNA is significantly correlated with poor prognosis [2].

In conclusion, Cenpl is essential for the mitotic process in eukaryotic cells. Through studies on cancer models, it has been revealed that Cenpl plays a significant role in the development and prognosis of multiple cancers, making it a potential biomarker and therapeutic target for cancer treatment [1-7, 9].